Treatment Set TS331634 (Antigen Laboratories, Inc.)
Welcome to the PulseAid listing for the Treatment Set TS331634 drug offered from Antigen Laboratories, Inc.. This Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [Chemical/Ingredient],Insect Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Antigen Laboratories, Inc. |
NON-PROPRIETARY NAME: | Treatment Set TS331634 |
SUBSTANCE NAME: | DERMATOPHAGOIDES FARINAE; CYNODON DACTYLON POLLEN; ALTERNARIA ALTERNATA; SORGHUM HALEPENSE POLLEN; IVA ANNUA VAR. ANNUA POLLEN; COCHLIOBOLUS SATIVUS; PHOMA DESTRUCTIVA; PLEOSPORA HERBARUM |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [Chemical/Ingredient],Insect Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [Chemical/Ingredient],Allergens [Chemical/Ingredient] |
ROUTE: | INTRADERMAL; SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 1986-10-31 |
END MARKETING DATE: | 0000-00-00 |
Treatment Set TS331634 HUMAN PRESCRIPTION DRUG Details:
Item Description | Treatment Set TS331634 from Antigen Laboratories, Inc. |
LABELER NAME: | Antigen Laboratories, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 2000; 80; .0004; .01; .01; .002; .002; .002([AU]/mL; [BAU]/mL; g/mL; g/mL; g/mL; g/mL; g/mL; g/mL) |
START MARKETING DATE: | 1986-10-31 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 49288-0720_b29faef0-2249-45b7-974b-212faa8c91d8 |
PRODUCT NDC: | 49288-0720 |
APPLICATION NUMBER: | BLA102223 |
Other DERMATOPHAGOIDES FARINAE; CYNODON DACTYLON POLLEN; ALTERNARIA ALTERNATA; SORGHUM HALEPENSE POLLEN; IVA ANNUA VAR. ANNUA POLLEN; COCHLIOBOLUS SATIVUS; PHOMA DESTRUCTIVA; PLEOSPORA HERBARUM Pharmaceutical Manufacturers / Labelers: